FDA and Medical Device Agents: Why Your Data Estate Assessment Must Precede Any Agent Pilot
April 29, 2026
The FDA does not have a regulation called “AI Agent Security.” There is no 510(k) pathway for an internally deployed operational agent. There is no predicate device that tells you exactly how to validate an agent that helps your quality team identify manufacturing anomalies.
But the FDA does have clear expectations for AI-powered systems in medical device operations — expectations that were articulated in their 2021 AI/ML Action Plan and have been refined through subsequent guidance documents, 510(k) review correspondence, and inspection findings. Those expectations do not become less applicable because your organization’s agents are operational rather than device-facing. They apply to any AI system that touches data in a regulated medical device environment.
The foundational expectation — the one that sits underneath everything else — is that you understand the data your AI system is trained on and operates with. You can document its lineage. You can verify its quality. You can explain the connection between the data and the system’s outputs.
For most medical device companies, that foundational expectation is where the problem starts.
What FDA Expects From AI-Powered Systems
FDA’s 2021 Artificial Intelligence and Machine Learning Action Plan established a framework for AI-based software in medical devices that rests on five core principles: validation and verification of AI system performance, data quality and integrity of training and operational data, transparency and explainability of AI system outputs, monitoring for performance drift over time, and risk management appropriate to the intended use.
These principles were written with device-facing AI in mind — clinical decision support tools, image analysis algorithms, diagnostic outputs. But they reflect FDA’s broader expectations about how any AI system operating in a regulated medical device environment should be governed. The same regulator that expects you to validate a software device’s algorithm expects you to have a governance framework for the AI tools your organization uses to support that device’s development, manufacturing, and quality management.
When FDA inspectors ask about AI usage in your operations — and this question is increasingly part of inspection preparation conversations — they want to understand: who authorized the AI tool’s use, what data is it accessing, how is its output being validated before it influences a regulated decision, what is the audit trail?
If you have deployed an agent into your operations — for document review, for manufacturing quality analysis, for regulatory submission support — and you cannot answer these questions, you have a compliance gap that is not theoretical.
The specific questions FDA asks in inspection and 510(k) review contexts include: how do you validate AI recommendations before they influence product quality decisions, how do you ensure the data the AI is trained on or accessing is of sufficient quality, how do you detect if AI system performance changes over time, and how do you explain AI-influenced decisions to qualified personnel who need to exercise professional judgment?
You cannot answer these questions without first understanding your data estate. What data does the agent access? Where did it come from? What is its quality status? Who authorized the agent to access it? Is there an audit trail?
The Data Estate Challenge for Medical Device Agents
Medical device companies operate with some of the most complex and consequential data environments of any regulated industry. They hold patient data protected under HIPAA. They hold clinical trial data regulated under 21 CFR Part 11. They hold quality and manufacturing data that feeds directly into device safety determinations. They hold design history files, device master records, and complaint records that regulators can request at any time.
When an agent is deployed into this environment, the data governance question is not just a security question. It is a validation question, a quality question, and a regulatory question.
Consider a specific scenario. A medical device quality team wants to deploy an agent to identify patterns in manufacturing non-conformances — to find signals in the data that might predict quality escapes before they become field failures. This is a legitimate, valuable use case. The agent could genuinely improve product quality and patient safety.
To deploy this agent responsibly in an FDA-regulated environment, the team needs to answer: where is the non-conformance data, is it complete (does it capture all non-conformances or only those entered through a specific system), is it accurate (are the categorizations consistent across operators and time periods), what is its quality status (has it been through any data quality review), and can the agent’s outputs be traced back to specific data inputs so that a quality engineer can validate the pattern it identified?
Most medical device companies cannot answer all of these questions about their non-conformance data. Not because they are negligent — but because their data was collected for operational purposes over many years, in multiple systems, by multiple teams, with varying levels of consistency. It was never designed to be an agent training dataset.
The shadow data problem is particularly acute. Medical device companies have copies of quality records in email attachments, local drives, analytical databases, and collaboration tools that were never intended to be permanent records but have persisted because nobody manages the data lifecycle systematically. An agent that can reach these shadow copies of regulated data creates a validation problem — you cannot validate the agent’s outputs if you cannot fully characterize what data it accessed.
"You cannot validate an agent's outputs if you cannot fully characterize what data it accessed. That is not a security requirement. It is an FDA requirement."
Why Assessment Must Come Before Deployment
The sequence matters enormously for medical device companies. In highly regulated environments, the cost of discovering a compliance gap after deployment is far higher than the cost of preventing it through pre-deployment assessment. Post-deployment remediation in a regulated environment requires documented change control, re-validation, and potentially notification to FDA if the change affects a cleared device’s functionality.
Pre-deployment assessment establishes the baseline. It answers the foundational questions: what data does the agent have access to, where does that data come from, what is its quality status, what are the access controls, what is the audit trail.
The data estate assessment for a medical device company focuses on five specific areas.
First, regulated data inventory. What data in your environment falls under FDA regulatory requirements — 21 CFR Part 11 electronic records, complaint records, clinical data, device history records? Is all of this data accurately inventoried, or is there shadow data in locations your formal records management does not account for?
Second, data lineage documentation. For data that an agent would access or be trained on, can you document where it came from, how it was processed, and what quality review it has undergone? This is the data lineage FDA expects you to be able to provide.
Third, access control mapping. Who has access to your regulated data, how is that access controlled, and what would an agent inherit if deployed with current user permissions? Overprivileged access in a medical device environment is not just a security risk — it is a validation risk, because agent outputs influenced by incorrectly accessed data may not be valid.
Fourth, audit trail coverage. Can you produce a complete audit trail of agent activity — what it accessed, when, in response to what queries — in a format that meets 21 CFR Part 11 requirements for electronic records? Most current agent deployments do not produce Part 11-compliant audit trails by default.
Fifth, quality status of training data. If you are training or fine-tuning an agent on quality or clinical data, has that data been through a formal quality review process? Using unreviewed data to train or prime an agent creates the same risks as using unreviewed data in any other analytical process in a regulated environment.
FDA expects you to understand and control the data behind your agent outputs. Does your data estate support that requirement?
Building Safety Into Your Agent Strategy
Medical device companies that build agents responsibly — and there are real use cases where agents deliver genuine value in device development, quality management, and regulatory operations — share a common starting point: they know their data before they deploy their agents.
They have mapped their regulated data. They know where it lives, what quality review it has undergone, what access controls govern it, and what audit trail it produces. They have resolved the shadow data problem — not necessarily by eliminating all informal data copies, but by clearly defining which data is within scope for agent access and ensuring that scope is well-controlled.
They treat agent deployment as a quality event — with the same structured change control, validation planning, and risk assessment that any other significant system change in a regulated environment receives.
And they build the audit trail into the deployment from the start rather than trying to retrofit it afterward.
FDA expectations on AI will tighten. The 2021 Action Plan has been followed by additional guidance, and the regulatory community internationally — through IMDRF and equivalent bodies — is developing more specific requirements. Medical device companies that build their AI governance foundation now will be ahead of those requirements when they arrive.
Medical device agents are not a compliance problem waiting to be avoided. They are a capability with real value — and a compliance obligation that must be addressed before deployment rather than after.
The data estate assessment is the starting point. It maps your regulated data, identifies your shadow data, evaluates your access controls and audit trail coverage, and produces the foundation documentation you will need when FDA asks about your AI governance.
Get your data estate and AI readiness assessment. We will map your data to FDA’s expectations and build the compliance foundation for safe agent deployment in your regulated environment.
Recent Posts
Have Any Question?
Call or email Cocha. We can help with your cybersecurity needs!
- (281) 607-0616
- info@cochatechnology.com
About the Author:
Steve Combs
Co-Founder & Managing Director, Cocha Technology
Steven is a fractional CIO/CISO with 30+ years of enterprise IT and security leadership. He has built AI governance frameworks for organizations with 1,700+ users, led enterprise Microsoft Copilot deployments, and conducted security assessments across law firms, energy companies, financial institutions, and PE-backed manufacturers.